Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
July 02, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
Engitix appoints two additional international biotech industry leaders as Scientific Advisors
June 25, 2024 04:00 ET
|
Engitix Therapeutics
LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:30 ET
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
March 21, 2024 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024 02:05 ET
|
Boehringer Ingelheim
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...
AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis
February 05, 2024 03:00 ET
|
AnaMar AB
LUND, Sweden, Feb. 05, 2024 (GLOBE NEWSWIRE) -- AnaMar, a clinical-stage biotech company developing first-in-class anti-fibrotic 5-HT2B receptor antagonists, announces that the European Medicines...
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
January 22, 2024 07:00 ET
|
Sagimet Biosciences Inc.
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis Primary efficacy...
GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis
December 14, 2023 03:29 ET
|
GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing...
Engitix Announces Appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer
September 05, 2023 07:00 ET
|
Engitix Therapeutics
LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary...